La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
65 hedge funds and large institutions have $78.9M invested in La Jolla Pharmaceutical Company in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 22 reducing their positions, and 6 closing their positions.
104% more call options, than puts
Call options by funds: $251K | Put options by funds: $123K
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 64 → 65 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less capital invested
Capital invested by funds: $82.1M → $78.9M (-$3.14M)
14% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$793K |
| 2 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
+$541K |
| 3 |
Renaissance Technologies
New York
|
+$508K |
| 4 |
PAM
Premier Asset Management
Chicago,
Illinois
|
+$329K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$195K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.09M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
-$340K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$164K |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$118K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$113K |
LJPC Hedge Fund Activity: Q4 2020 in Review
65 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q4 2020, worth a combined $78.9M — down 3.8% from $82.1M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LJPC positions and 6 closed out — a net gain of 1 holder — while 19 added to existing stakes and 22 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $793K. The largest seller was Morgan Stanley, cutting an estimated $2.09M.
- 65 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q4 2020, up from 64 in Q3 2020.
- Funds reported $78.9M of La Jolla Pharmaceutical Company stock for Q4 2020, down 3.8% quarter-over-quarter.
- 7 funds opened new La Jolla Pharmaceutical Company positions in Q4 2020 and 6 closed out, a net change of +1 holder.
- The largest La Jolla Pharmaceutical Company buyer in Q4 2020 was D.E. Shaw & Co, an estimated $793K added.
- The largest La Jolla Pharmaceutical Company seller in Q4 2020 was Morgan Stanley, an estimated $2.09M sold.
Based on aggregated 13F filings for Q4 2020.